MDMA Testifies on SBIR Reauthorization

MDMA testified before the House of Representatives Committee on Small Business regarding reauthorization of the Small Business Innovation Research (SBIR) program. MDMA's testimony focused on the importance the program has had in the development of medical technologies. MDMA also recommended that the reauthorization legislation include changes to current law and regulations including an increase in Phase I and Phase II grant levels and refining the small business ownership definition to include businesses with a majority ownership by venture capital investors.